BR0311178A - Regiões intergênicas como sìtios de inserção no genoma do vìrus vacìnia ancara modificado (mva) - Google Patents

Regiões intergênicas como sìtios de inserção no genoma do vìrus vacìnia ancara modificado (mva)

Info

Publication number
BR0311178A
BR0311178A BR0311178A BR0311178A BR0311178A BR 0311178 A BR0311178 A BR 0311178A BR 0311178 A BR0311178 A BR 0311178A BR 0311178 A BR0311178 A BR 0311178A BR 0311178 A BR0311178 A BR 0311178A
Authority
BR
Brazil
Prior art keywords
mva
genome
vaccinia virus
insertion sites
intergenic regions
Prior art date
Application number
BR0311178A
Other languages
English (en)
Other versions
BRPI0311178B1 (pt
BRPI0311178B8 (pt
Inventor
Paul Howley
Sonja Leyrer
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of BR0311178A publication Critical patent/BR0311178A/pt
Publication of BRPI0311178B1 publication Critical patent/BRPI0311178B1/pt
Publication of BRPI0311178B8 publication Critical patent/BRPI0311178B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

"REGIõES INTERGêNICAS COMO SìTIOS DE INSERçãO NO GENOMA DO VìRUS VACìNIA ANCARA MODIFICADO (MVA)". A presente invenção refere-se a novos sítios de inserção úteis para a integração de seq³ências exógenas no genoma do vírus Vacínia Ancara Modificado (MVA). A presente invenção fornece ainda vetores plasmideais para inserir o DNA exógeno no genoma do MVA. Além disso, a presente invenção fornece MVA recombinante que compreende uma seq³ência exógena de DNA inserida no novo dito sítio de inserção como medicina ou vacina.
BRPI0311178A 2002-05-16 2003-05-14 regiões intergênicas como sítios de inserção no genoma do vírus vacínia ancara modificado (mva) BRPI0311178B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200200753 2002-05-16
DKPA200200753 2002-05-16
DKPA200200752 2002-05-16
DKPA200200752 2002-05-16
PCT/EP2003/005045 WO2003097845A1 (en) 2002-05-16 2003-05-14 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)

Publications (3)

Publication Number Publication Date
BR0311178A true BR0311178A (pt) 2005-03-29
BRPI0311178B1 BRPI0311178B1 (pt) 2020-11-17
BRPI0311178B8 BRPI0311178B8 (pt) 2021-05-25

Family

ID=29551228

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0310051A BR0310051A (pt) 2002-05-16 2003-05-14 Poxvìrus recombinante expressando genes homólogos inseridos no genoma poxviral
BRPI0311178A BRPI0311178B8 (pt) 2002-05-16 2003-05-14 regiões intergênicas como sítios de inserção no genoma do vírus vacínia ancara modificado (mva)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0310051A BR0310051A (pt) 2002-05-16 2003-05-14 Poxvìrus recombinante expressando genes homólogos inseridos no genoma poxviral

Country Status (23)

Country Link
US (14) US7338662B2 (pt)
EP (3) EP1506301B1 (pt)
JP (4) JP4693092B2 (pt)
KR (4) KR20120002627A (pt)
CN (6) CN101831411A (pt)
AT (1) ATE315660T1 (pt)
AU (4) AU2003236646B2 (pt)
BR (2) BR0310051A (pt)
CA (3) CA2481521C (pt)
DE (1) DE60303218T2 (pt)
DK (2) DK1407033T3 (pt)
EA (3) EA012160B1 (pt)
ES (1) ES2256776T3 (pt)
HK (2) HK1076642A1 (pt)
IL (4) IL164177A0 (pt)
MX (2) MXPA04011194A (pt)
NO (3) NO334273B1 (pt)
NZ (2) NZ536501A (pt)
PL (2) PL218318B1 (pt)
PT (1) PT1407033E (pt)
SI (1) SI1407033T1 (pt)
UA (1) UA82479C2 (pt)
WO (2) WO2003097845A1 (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4101327C1 (pt) * 1991-01-18 1991-10-24 Mercedes-Benz Aktiengesellschaft, 7000 Stuttgart, De
HU230198B1 (hu) 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
PL220781B1 (pl) * 2002-04-19 2016-01-29 Bavarian Nordic As Zastosowanie wirusa krowianki Ankara (MVA) szczepu MVA-BN
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
EP1506301B1 (en) 2002-05-16 2014-04-30 Bavarian Nordic A/S Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
DE60320520T3 (de) * 2002-09-05 2019-05-09 Bavarian Nordic A/S Verfahren zur amplifikation von einem poxvirus in serumfreien verhältnissen
EP1601333B1 (en) * 2003-02-20 2013-01-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Novel insertion sites in pox vectors
GB2402391A (en) * 2003-06-04 2004-12-08 Oxxon Pharmaccines Ltd Fowlpox recombinant genome
WO2006052826A2 (en) * 2004-11-05 2006-05-18 The Government Of The United States Of America As Represented By The Secretary Methods for preparing cells and viruses
WO2006089690A1 (en) * 2005-02-23 2006-08-31 Bavarian Nordic A/S Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents
BRPI0711898A2 (pt) * 2006-05-19 2011-12-27 Glycofi Inc composiÇço de proteÍna da eritropoietina substancialmente homogÊnea, composiÇço farmacÊutica, e, mÉtodos de aumentar hematàcrito em um mamÍfero, e de produzir uma composiÇço de eritropoietina
WO2008142479A2 (en) * 2006-08-25 2008-11-27 The Government Of The United States Of Amercia, As Represented By The Secretary, Department Of Health And Human Services Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
US8440202B2 (en) * 2006-11-09 2013-05-14 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using the prime-boost approach
US8241638B2 (en) * 2006-11-09 2012-08-14 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using the prime-boost approach
CL2008000249A1 (es) * 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
BRPI0810305A2 (pt) * 2007-05-15 2018-07-10 Transgene Sa "vetor, molécula de ácido nucléico substancialmente isolada, célula hospedeira, composição farmacêutica, uso de uma molécula de ácido nucléico, uso de um vetor, uso de uma célula hospedeira e uso de uma composição"
TW200907058A (en) * 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
MX2009013030A (es) * 2007-05-30 2010-03-25 Wyeth Llc Poxvirus de mapache que expresa genes de antigenos felinos.
CA2702586C (en) 2007-10-18 2017-08-01 Bn Immunotherapeutics Inc. Use of mva to treat prostate cancer
WO2009152969A1 (en) * 2008-06-20 2009-12-23 Bavarian Nordic A/S Recombinant modified vaccinia virus measles vaccine
KR100894430B1 (ko) * 2008-11-11 2009-04-22 시스템디엔디(주) 초음파, 음향 및 온도변화를 이용한 밸브의 유체누설 측정장치 및 이를 이용한 유체누설 측정방법
DK2352834T3 (en) * 2008-11-21 2017-03-13 Bavarian Nordic As VECTOR INCLUDING MULTIPLE HOMOLOGICAL NUCLEOTIDE SEQUENCES
EP2486138A1 (en) 2009-10-08 2012-08-15 Bavarian Nordic A/S Generation of a broad t-cell response in humans against hiv
DK2488649T3 (da) 2009-10-16 2019-06-17 Us Health Rekombinant modificeret vaccinia ankara (mva)-vaccinia-virus indeholdende restrukturerede insertionssteder
WO2011087839A1 (en) 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
CN103118709A (zh) * 2010-03-26 2013-05-22 新兴产品开发盖瑟斯堡有限公司 流感病毒基质2蛋白的胞外域、其表达系统和应用
DK2596099T3 (da) 2010-07-20 2020-02-24 Bavarian Nordic As Fremgangsmåde til høst af ekspressionsprodukter
WO2012040474A2 (en) * 2010-09-23 2012-03-29 Baxter International Inc. Recombinant viral vectors and methods for inducing an immune response to yellow fever virus
CA2813685A1 (en) 2010-10-15 2012-04-19 Josef Weigl Recombinant modified vaccinia virus ankara influenza vaccine
CA2836299A1 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
JP2015520175A (ja) 2012-06-05 2015-07-16 ジ・オーストラリアン・ナショナル・ユニバーシティー インターロイキン−４アンタゴニストを伴うワクチン接種
NZ704005A (en) 2012-08-01 2016-07-29 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
EP2908851A1 (en) 2012-10-19 2015-08-26 Bavarian Nordic Inc. Methods and compositions for the treatment of cancer
WO2014139587A1 (en) * 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
RU2662927C2 (ru) * 2013-03-15 2018-07-31 Симентис Лимитед Иммунная модуляция
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
KR101645642B1 (ko) 2014-10-16 2016-08-11 대한민국 Kvac１０３ 유래의 재조합 백시니아 바이러스
KR101623498B1 (ko) 2014-10-16 2016-05-24 대한민국 약독화 백시니아 바이러스주 kvac１０３
BR112017018160A2 (pt) 2015-02-25 2018-04-10 Memorial Sloan-Kettering Cancer Center uso do vírus vaccinia ankara modificado (mva) não replicante inativado como monoimunoterpia ou em combinação com agentes de bloqueio de pontos de verificação imunológica para tumores sólidos
WO2016168862A1 (en) 2015-04-17 2016-10-20 Memorial Sloan-Kettering Cancer Center Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors
KR20160140075A (ko) * 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
BR112017026649A2 (pt) * 2015-06-15 2018-08-28 Bavarian Nordic As vacina de vírus de febre aftosa (fmdv) de vírus vaccinia ankara modificado (mva) recombinante
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN106591361A (zh) * 2015-10-20 2017-04-26 钱文斌 一种重组痘溶瘤病毒及其构建方法和应用
EP3402802B1 (en) 2016-01-08 2023-04-12 Geovax, Inc. Compositions and methods for generating an immune response to a tumor associated antigen
HUE059343T2 (hu) 2016-01-29 2022-11-28 Bavarian Nordic As Rekombináns, módosított Ankara Vaccinia vírus (MVA) és ló encephalitis vírus oltóanyag
WO2017136419A1 (en) * 2016-02-03 2017-08-10 Geovax Inc. Compositions and methods for generating an immune response to a flavivirus
BR112018016948A2 (pt) 2016-02-25 2019-01-08 Memorial Sloan Kettering Cancer Center mva recombinante ou mva¿e3l que expressa flt3l humano e uso do mesmo como agente imunoterapêutico contra tumores sólidos
CN116440176A (zh) 2016-02-25 2023-07-18 纪念斯隆凯特琳癌症中心 具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒
AU2017259259B2 (en) 2016-05-02 2020-11-19 Bavarian Nordic A/S Therapeutic HPV vaccine combinations
MA45994A (fr) * 2016-08-19 2021-03-17 Sementis Ltd Vaccins contre des virus
EP3518656A4 (en) * 2016-09-30 2020-09-30 Monsanto Technology LLC METHOD OF SELECTING TARGETS FOR SITE-SPECIFIC GENOME MODIFICATION IN PLANTS
WO2018209315A1 (en) 2017-05-12 2018-11-15 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
CN110958887B (zh) * 2017-06-15 2023-10-31 扬森疫苗与预防公司 编码hiv抗原的痘病毒载体及其使用方法
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
CN112512569A (zh) * 2018-05-11 2021-03-16 希望之城 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途
CN111979204B (zh) * 2019-05-24 2023-10-13 杭州功楚生物科技有限公司 携带海绵凝集素基因的溶瘤痘苗病毒、构建方法及用途
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
US20210299245A1 (en) * 2020-03-31 2021-09-30 Sementis Limited Attenuated poxvirus vector based vaccine for protection against covid-19
US20240033347A1 (en) 2022-07-08 2024-02-01 Viromissile, Inc. Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
JPH0795956B2 (ja) * 1986-09-22 1995-10-18 京都大学長 ポックスウイルス由来発現制御領域
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5225336A (en) * 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5651972A (en) 1989-04-21 1997-07-29 University Of Florida Research Foundation, Inc. Use of recombinant swine poxvirus as a live vaccine vector
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US6893845B1 (en) * 1990-09-28 2005-05-17 Applied Molecular Evolution, Inc. Surface expression libraries of heteromeric receptors
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
BE1004877A3 (fr) * 1991-05-27 1993-02-16 Solvay Virus de l'avipox recombinant, culture de cellules infectees par ce virus et vaccins pour la volaille derives de ce virus.
FR2679249B1 (fr) * 1991-07-15 1993-11-26 Centre Nal Recherc Scientifique Souches de levure avec integration stable de genes heterologues.
AU670538B2 (en) 1991-07-26 1996-07-25 Virogenetics Corporation Infectious bursal disease virus recombinant poxvirus vaccine
DE69229390T2 (de) * 1991-08-26 1999-11-11 Immuno Ag Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus
DE69133333T2 (de) * 1991-08-26 2004-07-29 Baxter Healthcare S.A. Ein intaktes FPV-tk-Gen enthaltender rekombinanter Virus der Vogelpocken
US5676950A (en) 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
EP0753581A1 (en) * 1995-07-10 1997-01-15 Immuno Ag Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
DE19629828A1 (de) * 1996-07-24 1998-01-29 Bayer Ag Carbanilide
AU4556597A (en) * 1996-09-24 1998-04-17 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
AUPP380598A0 (en) * 1998-05-29 1998-06-25 Commonwealth Scientific And Industrial Research Organisation Genetically manipulated entomopoxvirus
US6252871B1 (en) 1998-07-01 2001-06-26 Powerwave Technologies, Inc. Switchable combiner/splitter
US20040265324A1 (en) * 1999-03-23 2004-12-30 Cardosa Mary Jane Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
WO2000073476A1 (en) * 1999-05-28 2000-12-07 Gsf Forschungszentrum Für Umwelt Und Gesundheit Gmbh Vector for integration of heterologous sequences into poxviral genomes
EE05633B1 (et) * 2000-03-14 2013-02-15 Mayr Anton Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
IL154169A0 (en) 2000-08-29 2003-07-31 Wyeth Corp Packaging of positive-strand rna virus replicon particles
HU230198B1 (hu) * 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
EP1506301B1 (en) 2002-05-16 2014-04-30 Bavarian Nordic A/S Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
ATE365220T1 (de) * 2002-11-25 2007-07-15 Bavarian Nordic As Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus

Also Published As

Publication number Publication date
AU2009200380C1 (en) 2010-03-11
CN102199628A (zh) 2011-09-28
US20060165727A1 (en) 2006-07-27
AU2003236646B2 (en) 2009-01-15
JP4895505B2 (ja) 2012-03-14
DE60303218D1 (de) 2006-04-06
BRPI0311178B1 (pt) 2020-11-17
CN102719408A (zh) 2012-10-10
PL218318B1 (pl) 2014-11-28
DK1506301T3 (da) 2014-07-21
JP2011004755A (ja) 2011-01-13
EA200900180A1 (ru) 2009-08-28
HK1076836A1 (en) 2006-01-27
AU2008255213A1 (en) 2009-01-08
IL164172A0 (en) 2005-12-18
PL372093A1 (en) 2005-07-11
CN1653183A (zh) 2005-08-10
PL216760B1 (pl) 2014-05-30
SI1407033T1 (sl) 2006-06-30
US20130243813A1 (en) 2013-09-19
KR101005630B1 (ko) 2011-01-05
NZ536502A (en) 2005-10-28
US8288125B2 (en) 2012-10-16
CN1653183B (zh) 2012-07-25
UA82479C2 (uk) 2008-04-25
NO20045480L (no) 2004-12-16
US20120178157A1 (en) 2012-07-12
US20110053260A1 (en) 2011-03-03
KR101138067B1 (ko) 2012-04-24
US20100303856A1 (en) 2010-12-02
CN102703393A (zh) 2012-10-03
EP1506301A1 (en) 2005-02-16
US9109233B2 (en) 2015-08-18
US7550147B2 (en) 2009-06-23
KR101041691B1 (ko) 2011-06-14
US8309326B2 (en) 2012-11-13
MXPA04011194A (es) 2005-02-14
AU2009200380B2 (en) 2009-10-01
NO336489B1 (no) 2015-09-07
US8034354B2 (en) 2011-10-11
JP2005525823A (ja) 2005-09-02
EA020230B1 (ru) 2014-09-30
US20100173388A1 (en) 2010-07-08
WO2003097846A1 (en) 2003-11-27
CA2481521C (en) 2012-04-17
DE60303218T2 (de) 2006-09-14
IL193088A0 (en) 2009-02-11
AU2008255213B2 (en) 2011-10-06
EP2253709B1 (en) 2018-04-11
EA200401506A1 (ru) 2005-04-28
CN100494388C (zh) 2009-06-03
JP4693092B2 (ja) 2011-06-01
US8414900B2 (en) 2013-04-09
BR0310051A (pt) 2005-02-15
CA2481521A1 (en) 2003-11-27
CA2481799A1 (en) 2003-11-27
IL193088A (en) 2015-02-26
HK1076642A1 (en) 2006-01-20
US8435543B2 (en) 2013-05-07
AU2009200380A1 (en) 2009-02-19
JP2005525822A (ja) 2005-09-02
EA007811B1 (ru) 2007-02-27
US20120039936A1 (en) 2012-02-16
US20120082696A1 (en) 2012-04-05
US7964374B2 (en) 2011-06-21
MXPA04010713A (es) 2005-03-07
NO20044940L (no) 2004-11-12
US20110053259A1 (en) 2011-03-03
US20110244574A1 (en) 2011-10-06
AU2003242540A1 (en) 2003-12-02
US20110250693A1 (en) 2011-10-13
EA200401507A1 (ru) 2005-06-30
IL164177A0 (en) 2005-12-18
CN1653184A (zh) 2005-08-10
EP2253709A1 (en) 2010-11-24
JP2010259446A (ja) 2010-11-18
WO2003097845A1 (en) 2003-11-27
BRPI0311178B8 (pt) 2021-05-25
NO20111324A1 (no) 2011-09-29
IL193087A0 (en) 2009-02-11
US20120135501A1 (en) 2012-05-31
ES2256776T3 (es) 2006-07-16
NZ536501A (en) 2006-08-31
EP1407033B1 (en) 2006-01-11
US7338662B2 (en) 2008-03-04
EA012160B1 (ru) 2009-08-28
CA2812019A1 (en) 2003-11-27
US20050244428A1 (en) 2005-11-03
EP1407033A1 (en) 2004-04-14
US20090311746A1 (en) 2009-12-17
IL193087A (en) 2012-10-31
NO334273B1 (no) 2014-01-27
ATE315660T1 (de) 2006-02-15
CN101831411A (zh) 2010-09-15
EP1506301B1 (en) 2014-04-30
JP5777199B2 (ja) 2015-09-09
CA2481799C (en) 2014-01-28
PT1407033E (pt) 2006-05-31
KR20040108798A (ko) 2004-12-24
KR20120002627A (ko) 2012-01-06
KR20100110901A (ko) 2010-10-13
AU2003236646A1 (en) 2003-12-02
DK1407033T3 (da) 2006-05-22
US8741308B2 (en) 2014-06-03
PL372088A1 (en) 2005-07-11
KR20040108809A (ko) 2004-12-24

Similar Documents

Publication Publication Date Title
BR0311178A (pt) Regiões intergênicas como sìtios de inserção no genoma do vìrus vacìnia ancara modificado (mva)
HUS1600010I1 (hu) Módosított Vacciniavírus Ankara variáns
ATE228016T1 (de) Lebendvakzine zur behandlung von tumorerkrankungen
NO20013102D0 (no) Gener, proteiner og deres anvendelse
UA104993C2 (uk) Рекомбінантний поксвірус, який експресує гомологічні гени, вставлені в поксвірусний геном
FR2809960B1 (fr) Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
AP2003002944A0 (en) Method to generate non virulent microorganisms from pathogenic ones through permanent genetic modification of their biological membrane for vaccine production.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/05/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2775 DE 12/03/2024 POR TER SIDO INDEVIDA.